GLTO Galecto

Galecto to Participate in SVB Securities Global Biopharma Conference

Galecto to Participate in SVB Securities Global Biopharma Conference

BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present at the upcoming SVB Securities Global Biopharma Conference taking place on February 14-16, 2023. Details for the event are as follows:

SVB Securities Global Biopharma Conference

Date:Tuesday, February 14th, 2023
Time:8:00 AM EST
Webcast:     
  

A live webcast of the presentation will be available on the “News & Events” section of Galecto’s Investor website at . A replay of the presentation will be available on this same website following the event.

About Galecto

Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has four ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2 trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a Phase 1b/2a trial in liver cirrhosis; and (iv) an orally active galectin-3 inhibitor (GB1211) in a separate Phase 2 trial for the treatment of non-small cell lung cancer (NSCLC) in combination with atezolizumab (Tecentriq®).

Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit .

For more information, contact:

Galecto, Inc. 
Hans Schambye, CEO

 
Jon Freve, CFO 
 
  
Investors/USMedia/EU
Ashley R. RobinsonSandya von der Weid
  


EN
01/02/2023

Underlying

GLTOGalecto

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galecto

 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Closing of Public Offering and Full Exercise of the ...

Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its previously announced underwritten public offering of 16,644,737 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 2,171,052 additional s...

February 12, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Pricing of $275 Million Underwritten Public Offering

Galecto Announces Pricing of $275 Million Underwritten Public Offering BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a public offering price of $19.00 per share. In addition, Galecto has granted the underwriters a 30-day option to purchase an a...

February 11, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Proposed Underwritten Public Offering of Common Stoc...

Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, Series C non-voting convertible preferred stock. All of the securities are being offered by Galecto. In addition, Galecto i...

February 10, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Highlights Key Strategic Priorities and Anticipated 2026 Miles...

Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administrationRecent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical OfficerPipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026Cash balance...

January 12, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Key Additions to Leadership Team

Galecto Announces Key Additions to Leadership Team Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for IND submission in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Cash balance, including $285 million raised in November 2025 PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinica...

January 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch